Novartis and Global Blood Therapeutics last year nabbed FDA approvals for new sickle cell disease drugs and tagged them with…More

Novo Nordisk bet big on its GLP-1 med Saxenda in obesity, despite rivals’ failures to expand the global market. But payers…More

Patients with epithelioid sarcoma previously had no targeted treatment options, but that’ll change with Epizyme’s approval for Tazverik. The FDA signed…More

It’s final: England won’t be covering AstraZeneca’s quick-selling Tagrisso in previously untreated non-small cell lung cancer patients with EGFR mutations.…More

Horizon Therapeutics is trying to shed its reputation as a primary care drugmaker and emerge with a brand-new life in…More

Merck was dealt a blow earlier this month when I-O superstar Keytruda missed its mark in a key late-stage trail…More

A New York drug distributor will no longer sell opioids, saying the legal costs associated with them are just too…More

Biogen hasn’t even filed its FDA application for controversial Alzheimer’s drug aducanumab yet. But it’s already started gearing up for…More